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Abstract
Background: Efficacy trials suggest that extra-fine particle beclometasone dipropionate-formoterol (efBDP-FOR) is comparable to
fluticasone propionate-salmeterol (FP-SAL) in preventing asthma exacerbations at a clinically equivalent dosage. However, switching from
FP-SAL to efBDP-FOR has not been evaluated in real-world asthma patients. 
Aims: The REACH (Real-world Effectiveness in Asthma therapy of Combination inHalers) study investigated the clinical and cost
effectiveness of switching typical asthma patients from FP-SAL to efBDP-FOR. 
Methods: A retrospective matched (1:3) observational study of 1,528 asthma patients aged 18–80 years from clinical practice databases
was performed. Patients remaining on FP-SAL (n=1,146) were compared with those switched to efBDP-FOR at an equivalent or lower
inhaled corticosteroid (ICS) dosage (n=382). Clinical and economic outcomes were compared between groups for the year before and
after the switch. Non-inferiority (at least equivalence) of efBDP-FOR was tested against FP-SAL by comparing exacerbation rates during
the outcome year. 
Results: efBDP-FOR was non-inferior to FP-SAL (adjusted exacerbation rate ratio 1.01 (95% CI 0.74 to 1.37)). Switching to efBDP-FOR
resulted in significantly better (p<0.05) odds of achieving overall asthma control (no asthma-related hospitalisations, bronchial infections,
or acute oral steroids; salbutamol ≤200μg/day) and lower daily short-acting β2-agonist usage at a lower daily ICS dosage (mean
–130μg/day FP equivalents; p<0.001). It also reduced mean asthma-related healthcare costs by £93.63/patient/year (p<0.001).  
Conclusions: Asthma patients may be switched from FP-SAL to efBDP-FOR at an equivalent or lower ICS dosage with no reduction in
clinical effectiveness but a significant reduction in cost.  
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Introduction 
Asthma is a complex and costly disease to manage, particularly in
patients with moderate-to-severe persistent asthma who require
combination therapy with an inhaled corticosteroid (ICS) and long-
acting β2-receptor agonist (LABA) for daily asthma control. For
example, in the East of England, a region of approximately 5.85
million people,1 the Strategic Health Authority reported in 2011 that
it spends approximately £55.5 million annually on low- and
moderate-dose combination ICS-LABA inhalers.2 Any measure that
reduces the cost of asthma therapy without reducing the
effectiveness or increasing the risk is therefore worthy of
consideration.   
In January 2008 an extra-fine particle formulation of
beclometasone dipropionate (efBDP) and formoterol (FOR) was
licensed in the UK as a fixed-dose combination (FDC) inhaler for use
in the treatment of asthma in adults.3 Extra-fine particle BDP-FOR
has several advantages over larger particle ICS-LABA combinations
such as fluticasone propionate and salmeterol (FP-SAL), the efBDP
and FOR components each contributing a clinical advantage.
First, pulmonary distribution – especially to the small airways – is
greater for extra-fine particle formulations than for larger particle
formulations.4-13 Second, and no doubt consequentially, efBDP is as
effective for asthma control as larger particle ICS formulations, at a
lower ICS dosage. For example, the clinical equivalence of efBDP
and FP in asthma patients can be described as a ratio of
approximately 0.8:1, so 400μg of efBDP is clinically equivalent to
500μg of FP.12-15 A third and probably related advantage is that extra-
fine particle inhalers may be less dependent on good inhaler
technique – or more tolerant of poor technique – than larger particle
formulations.7,16,17 Lastly, formoterol relieves bronchoconstriction
more quickly than salmeterol18,19 and almost as quickly as short-
acting β2-receptor agonists (SABA) such as salbutamol,19-21
potentially improving patient compliance and allowing the efBDP-
FOR inhaler to be used for both maintenance and reliever therapy
(MART) if the patient and physician elect this approach.22
In various studies, efBDP-FOR was at least as effective at
improving lung function and measures of asthma control while
preventing acute asthma exacerbations as (1) larger particle BDP
with FOR delivered via separate inhalers;23 (2) FP-SAL;12-16,24,25 and (3)
budesonide with formoterol (BUD-FOR).16,24,26,27 As further evidence,
in studies of ICS alone, efBDP was at least as effective for asthma
control as larger particle formulations of BDP28-30 and fluticasone.31
However, the greater clinical effectiveness of efBDP may have been
understated in efficacy studies involving randomised controlled trials
(RCTs), which have shown no clear clinical advantage of any one
ICS.32-34 In real-world asthma patients, efBDP provides equivalent –
and, in some cases, better – asthma control at a lower daily ICS
dosage,31,35 and therefore lower risk for adverse effects31 and lower
asthma-related healthcare costs35 – attributes considered important
by physicians and respiratory specialists alike when choosing an ICS-
LABA combination.36
Product approval for the efBDP-FOR inhaler was granted in the
UK based on RCTs in Europe which showed non-inferiority in
morning pre-dose peak expiratory flow and no significant difference
in the number of symptom-free days or adverse events, including
acute exacerbations, compared with FP-SAL15 and BUD-FOR.26
Because efBDP-FOR costs less than other FDC inhalers and has been
shown to be of comparable efficacy in asthma management, the UK
National Health Service (NHS) in some regions encouraged
physicians to switch patients to the efBDP-FOR inhaler in an effort
to lower the costs of ongoing ICS-LABA therapy.2 This switch was
estimated to save between £3 and £16 per patient per month
(depending on the inhaler) for low- and moderate-dose ICS-LABA
therapy.2
However, despite the reasonable assumption of greater cost
effectiveness with the efBDP-FOR inhaler, to date no studies have
investigated the outcome of such a switch under real-world
conditions of use. The clinical efficacy of switching from FP-SAL to
efBDP-FOR, with14 or without25 a step-down in ICS dosage, has been
shown in two recent RCTs, but it has yet to be demonstrated under
less controlled conditions.
We therefore undertook a retrospective study of typical asthma
patients seen in routine clinical practice in the UK, investigating both
the clinical and cost effectiveness of switching from FP-SAL to
efBDP-FOR at an equivalent or lower ICS dosage. Using nationwide
patient databases, we sought to generate as large and
representative a population of asthma patients as possible given the
study aims, including patients with significant co-morbidities, a past
or current smoking habit, and less than ideal adherence to their ICS
prescriptions.
Our aims were twofold: (1) to determine whether efBDP-FOR is
at least equivalent (non-inferior) to FP-SAL for exacerbation
prevention when typical asthma patients are switched from FP-SAL
to efBDP-FOR; and (2) to determine whether switching from FP-SAL
to efBDP-FOR is cost-effective or represents a trade-off (lower cost
but lower effectiveness). 
Methods 
Study design     
A retrospective matched observational study was conducted of
asthma patients in the UK treated in primary care practice. An
outline of the study design is illustrated in Figure 1. For each patient
meeting the inclusion criteria, the medical record was examined for
12 months before (‘baseline year’) and for 12 months after
(‘outcome year’) the face-to-face or electronic review during which
the physician either continued FP-SAL inhaler therapy at the same
ICS dosage or switched the patient to efBDP-FOR at an equivalent
or lower ICS dosage. The date of this pivotal patient review was
designated the index prescription date (IPD). For further explanation,
see Supplemental Materials (Appendix 1 available online at
www.thepcrj.org).
Raw data were obtained from the UK Optimum Patient Care
Research Database (http://www.optimumpatientcare.org/
Html_Docs/OPCRD.html) and the Clinical Practice Research Datalink,
formerly known as the General Practice Research Database
The full version of this paper, with online appendices, 
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(http://www.cprd.com/intro.asp), spanning the period from January
2007 to August 2012. Inclusion criteria are summarised in Box 1 and
further details are given in the online Supplemental Materials, along
with a CONSORT diagram illustrating the patient selection process
(Figure S1). A total of 50,261 patients met the inclusion criteria, of
whom 390 were switched to efBDP-FOR and 49,871 remained on
FP-SAL.
The patients switched to efBDP-FOR were then matched as
closely as possible in a ratio of 1:3 with those remaining on FP-SAL
using the demographic and clinical criteria summarised in Table 1.
Using a one-sided test of equivalence based on exacerbation
prevention, the 1:3 ratio yielded a statistical power of 95% whereas
lesser ratios yielded lower powers (93% and 86% for 1:2 and 1:1
ratios, respectively). A time-frame of ±2 years for the IPD was
deemed optimal for case matching, as a longer interval would have
risked placing matched patients in different time periods and a
shorter interval would have excluded too many otherwise eligible
patients. As it was, eight patients in the efBDP-FOR group were
excluded for unmatched data (see Figure S2 in online Supplemental
Materials), so the final group numbers were 382 patients switched
to efBDP-FOR and 1,146 patients remaining on FP-SAL for the
outcome year.
Clinical outcome measures      
The primary clinical outcome investigated was the incidence of
severe asthma exacerbations, as defined by the American Thoracic
Society and European Respiratory Society (ATS/ERS) task force on
asthma control and exacerbations, where an exacerbation is defined
as an occurrence of asthma-related hospital attendance/admission
(including Accident and Emergency attendance) or the use of acute
oral steroids.37 The secondary outcomes investigated are described in
Table 2. 
Economic outcome measures      
Health economic analyses comprised comparisons of asthma-related
healthcare costs and assessment of the cost effectiveness of
treatment, using exacerbation prevention (ATS/ERS definition) and
risk domain asthma control (see Table 2) as measures of treatment
effectiveness.
Asthma-related costs included all asthma drug prescriptions: ICS
of all kinds including FDC inhalers, oral corticosteroids for acute
control, SABA, LABA, leukotriene receptor antagonists, theophylline,
and antibiotics prescribed for lower respiratory tract infections. Drug
costs were obtained from the 2010 British National Formulary
(http://www.bnf.org/bnf/index.htm).
Asthma-related costs also included general practitioner (GP)
consultations and respiratory-related hospitalisation costs
Figure 1.  Schematic of the Real-world Effectiveness in
Asthma therapy of Combination inHalers (REACH) study
design
efBDP-FOR=extra-fine particle beclometasone and formoterol as fixed-dose
combination inhaler, FP-SAL=fluticasone and salmeterol as fixed-dose
combination inhaler, ICS=inhaled corticosteroid, SABA=short-acting 
β2-receptor agonist.
Age: 18–80 years
Diagnostic code: asthma; no code for chronic obstructive pulmonary 
disease or other chronic respiratory condition (except asthma)
Smoking status: known
Baseline fluticasone and salmeterol as fixed-dose combination inhaler 
(FP-SAL) therapy: >2 prescriptions for FP-SAL during baseline year
Oral steroids: none for maintenance during baseline year
Evidence of continuing therapy: >2 prescriptions for extra-fine particle 
beclometasone and formoterol as fixed-dose combination inhaler 
(efBDP-FOR) during outcome year (efBDP-FOR group); no change in 
therapy (FP-SAL group)
Evidence of switching for reasons other than efficacy: >5 patients in a 
practice switched from FP-SAL to efBDP-FOR, with no increase in 
inhaled corticosteroid dosage, in a 3-month period
Box 1. Inclusion criteria for the Real-world Effectiveness
in Asthma therapy of Combination inHalers (REACH) study
Criteria Specifics
Age ±5 years, within two subgroups: 
18–60 years and 61–80 years
Gender Male or female
Smoking status Non-smoker, current smoker, 
or ex-smoker
Last prescribed ICS dosage Exact match (μg/day)
prior to IPD
Type of consultation/review Face-to-face or electronic
at IPD
Last ICS device prescribed MDI or DPI
prior to IPD
Number of courses of acute 0, 1, or 2+
oral steroids
SABA usage, average 0, 1–200, 201–400, 401–800, 801+ μg
daily dose
Year of IPD Closest match within ±2 years
DPI=dry powder inhaler, ICS=inhaled corticosteroid, IPD=index prescription date, 
MDI=metered dose inhaler, SABA=short-acting β2-receptor agonist.
Table 1. Matching criteria for the Real-world
Effectiveness in Asthma therapy of Combination
inHalers (REACH) study
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(outpatient, inpatient, and Accident and Emergency). Unit costs for
GP consultations were derived from the Personal Social Services
Research Unit report: Unit Costs of Health and Social Care 2011,38
assuming an average consultation duration of 11.7 minutes.
Hospital usage costs were obtained from the NHS Reference Costs
2010–2011.39
Statistical analyses      
All analyses were carried out using SPSS Statistics Version 20 (IBM,
Armonk, New York, USA), SAS Version 9.3 (SAS Institute, Cary,
North Carolina, USA), and Microsoft Excel 2007 (Microsoft,
Redmond, Washington, USA). Statistically significant results were
defined as p<0.05, and trends as p>0.05 but <0.10. All adjusted
odds/rate ratios and differences in proportions are presented with
their 95% confidence intervals (CI).
Exploratory data analysis was conducted for all variables of
interest for the baseline and outcome years. Box 2 in the online
Supplemental Materials lists all the potential confounders examined.
Summary statistics for all baseline variables for the matched cohorts
were compared using conditional logistic regression (for more
information, see online Supplemental Materials).
Clinical outcomes 
For the primary outcome, the total number of exacerbations in the
outcome year was compared between treatment groups using a
conditional Poisson regression model to obtain an estimate of
relative exacerbation rates (further details are given in online
Supplemental Materials).
To show ‘at least equivalence’ or non-inferiority in exacerbation
prevention for efBDP-FOR compared with FP-SAL, the adjusted
proportions of patients within each treatment group and the
adjusted difference in proportions recording no exacerbations in the
outcome year were calculated using a conditional binary logistic
regression model. Non-inferiority was defined as the proportion of
efBDP-FOR patients recording no exacerbations being no more than
10% lower than the proportion of patients remaining on FP-SAL
recording no exacerbations. We chose a threshold of –10% based
on clinical experience and available literature. Although there is little
agreement among statisticians,40,41 differences of >10% are widely
regarded as clinically important in related respiratory studies.41
For the secondary outcomes, adjusted odds and rates of events
were compared between matched treatment groups using
conditional binary/ordinal logistic regression or conditional Poisson
regression models, respectively, as detailed in the online
Supplemental Materials.
Economic outcomes 
Generalised linear models with a logit link and gamma distribution
were used to estimate mean asthma-related healthcare costs.
Treatment costs were compared between groups via the differences
in mean costs/patient/year, both unadjusted and adjusted for
Outcome Definition
Risk domain asthma control ‘Controlled’ if absence of:
● asthma-related hospital attendance/admission,* and
● GP consultation for LRTI, and
● prescription for acute course of oral steroids
Overall asthma control (risk and impairment) ‘Controlled’ if:
● risk domain asthma control, and
● average SABA dosage of ≤200μg/day for salbutamol or ≤500μg/day for terbutaline
Severe exacerbation rate (clinical definition) ‘Exacerbation’ defined as an occurrence of:
● asthma-related hospital attendance/admission or
● GP consultation for LRTI or
● use of acute oral steroids
Treatment success ‘Successful’ if:
● risk domain asthma control and
● no additional or change in therapy†
Asthma-related hospitalisations Hospital admission‡ within 7 days either side of a lower respiratory code
Average daily SABA usage 0, 1–200, 201–400, 401–800, or 801+ μg
Adherence to ICS therapy§ <50%, 50–69%, 70–99%, or 100+%
Incidence of oral thrush Diagnostic code for oral candidiasis or prescription for topical/oral antifungal therapy
*Asthma-related hospitalisation included Accident and Emergency, out-of-hours, and Outpatient department attendance.
†Change in asthma therapy included an increase in ICS dose of >50% or the addition of theophylline or a leukotriene receptor antagonist.
‡Inpatient asthma-related or vague/uncoded hospitalisation.
§Adherence to ICS therapy was calculated as follows:
days per pack = actuations per pack/actuations per day
total pack days = sum (days per pack) over the year of interest
adherence (%) = (total pack days/365) x 100
GP=general practitioner, ICS=inhaled corticosteroid, LRTI=lower respiratory tract infection, SABA=short-acting β2-receptor agonist.
Table 2. Secondary outcomes compared between matched treatment groups
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potential confounders. Differences in adjusted mean costs are
reported with 95% CI found by bootstrapping methods42 using
1,000 random samples taken, with replacement, from the dataset. 
Cost effectiveness was determined using point estimates of
differences in treatment cost and effectiveness between efBDP-FOR
and FP-SAL using 1,000 replicated samples plotted to create a cost
effectiveness plane, with FP-SAL as the reference treatment.
Results
Baseline data 
Despite matching for most recent prescribed ICS dosage and several
other clinically relevant variables, some significant baseline differences
remained between treatment groups (Tables 3a–c). While the rates of
rhinitis and cardiac disease were higher in the patients who would
remain on FP-SAL, the patients who would be switched to efBDP-FOR
appeared to have slightly more severe asthma, as evidenced by a
higher rate of multiple asthma consultations, a greater number of
respiratory prescriptions (particularly for ICS and SABA), and a higher
average daily ICS dosage. The higher controller-to-reliever ratio in the
patients who would be switched to efBDP-FOR suggests that these
patients may have been more diligent in managing their asthma than
those who would remain on FP-SAL. Regardless, there were no
significant differences between treatment groups for any of the
clinical outcome measures at baseline (see Table 3b in online
Supplemental Materials).  
Daily ICS dosages at review/switch  
At the IPD, the majority of patients (71.2%) were on a prescribed FP
dosage of 500μg/day, 11.5% were on 200–250μg/day, and 17.3%
were on 1,000μg/day (Figure 2). These proportions did not change
going into the outcome year in the patients remaining on FP-SAL. In
the group switching to efBDP-FOR, 306 patients (80.1%) were
prescribed an efBDP dosage of 400μg/day and 76 patients (19.9%) a
dosage of 200μg/day (Figure 2). These dosages were equivalent to
the most recent FP-SAL prescription in 296 patients (77.5%), and in
the remaining 86 patients (22.5%) they represented a reduction in
ICS dosage of at least 50%. 
Primary outcome   
There was no significant difference between treatment groups in the
incidence of severe exacerbations during the outcome year (Table 4).
The adjusted difference in proportions of patients recording no
exacerbations was only 0.02 (95% CI –0.03 to 0.07). As the threshold
for non-inferiority was set at a difference of no more than 10% lower
(–0.10), efBDP-FOR was shown to be at least equivalent (non-inferior)
to FP-SAL in this setting
Secondary outcomes    
The efBDP-FOR patients were significantly more likely to achieve
overall asthma control, have lower daily SABA usage, and be more
adherent to ICS therapy than the FP-SAL patients (Table 5a; Figure 3).
In addition, the average daily ICS dosage over the course of the
outcome year was significantly lower in the efBDP-FOR group, by a
mean of 130μg/day in FP-equivalent doses (Table 6). 
There were no significant differences between treatment groups
for risk domain asthma control, severe exacerbations (clinical
definition), treatment success, inpatient asthma-related
Variable FP-SAL efBDP-FOR* p Value†
(n=1,146) (n=382)
Age at index prescription date (years)
18–60 723 (63.1%) 241 (63.1%) NA
61–80 423 (36.9%) 141 (36.9%)
Mean (SD) 53.4 (14.7) 53.4 (14.9) 0.86
Median (IQR) 53 (43, 65) 54 (43, 65)
Gender
Male 507 (44.2%) 169 (44.2%) NA
Female 639 (55.8%) 213 (55.8%)
Smoking status
Non-smoker 594 (51.8%) 198 (51.8%) NA
Current smoker 210 (18.3%) 70 (18.3%)
Ex-smoker 342 (29.9%) 114 (29.9%)
Last prescribed ICS dosage (actual FP dosage, μg/day)
200 99 (8.6%) 33 (8.6%) NA
250 33 (2.9%) 11 (2.9%)
500 816 (71.2 %) 272 (71.2%)
1,000 198 (17.3%) 66 (17.3%)
Mean (SD) 553.3 (223.6) 553.3 (223.7) NA
Median (IQR) 500 (500, 500) 500 (500, 500)
Type of consultation at index prescription date
Face-to-face 321 (28.0%) 107 (28.0%) NA
Electronic 825 (72.0%) 275 (72.0%)
Last prescribed ICS device
MDI 1,059 (92.4%) 353 (92.4%) NA
DPI 87 (7.6%) 29 (7.6%)
Courses of acute oral steroids
0 936 (81.7%) 312 (81.7%) NA
1 141 (12.3%) 47 (12.3%)
2+ 69 (6.0%) 23 (6.0%)
Mean (SD) 0.29 (0.76) 0.34 (1.13) 0.081
Median (IQR) 0 (0, 0) 0 (0, 0)
SABA usage, average daily dose (μg/day)
0 216 (18.9%) 72 (18.9%) NA
1–200 336 (29.3%) 112 (29.3%)
201–400 291 (25.4%) 97 (25.4%)
401–800 240 (20.9%) 80 (20.9%)
801+ 63 (5.5%) 21 (5.5%)
Mean (SD) 279.7 (289.2) 296.4 (348.2) 0.022
Median (IQR) 219 (55, 438) 219 (55, 438)
Year of index prescription date
2008 379 (33.0%) 26 (6.8%) <0.001
2009 702 (61.3%) 178 (46.6%)
2010 63 (5.5%) 151 (39.5%)
2011 2 (0.2%) 27 (7.1%)
Data are shown as n (%) unless otherwise indicated
*These patients were on FP-SAL during their baseline year but were switched 
to efBDP-FOR at the index prescription date.
†Conditional logistic regression.
DPI=dry powder inhaler, efBDP-FOR=extra-fine particle beclometasone and 
formoterol as fixed-dose combination inhaler, FP=fluticasone propionate, 
FP-SAL=fluticasone and salmeterol as fixed-dose combination inhaler, ICS=inhaled 
corticosteroid, IQR=interquartile range, MDI=metered dose inhaler, NA=not 
applicable (matching variable), SABA=short-acting β2-receptor agonist, 
SD=standard deviation.
Table 3a. Clinically important baseline variables in
matched treatment groups: variables used in patient
matching (see Tables 3b and 3c in online Supplemental
Materials for further baseline patient characterisation)
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hospitalisations, or incidence of oral thrush during the outcome year
(see Table 5b in online Supplemental Materials). There were no
significant interactions between treatment and smoking status for
any outcomes.
Health economic outcomes     
During the baseline year there were no significant differences
between treatment groups for asthma-related total healthcare or
drug costs. However, there was a trend (p=0.061) for higher
healthcare costs in the patients who would be switched to efBDP-
FOR, driven by significantly higher costs for their FDC inhalers
(p=0.016) and asthma consultations (p<0.001).
During the outcome year asthma-related total healthcare and
drug costs were both significantly lower in patients switched to
efBDP-FOR than in those remaining on FP-SAL (p<0.001 for both
indices). Adjusted for baseline costs, the mean asthma-related total
healthcare costs for the outcome year were £438.82/patient (95%
CI £421.94 to £456.25) for the FP-SAL group and £345.19/patient
(95% CI £327.96 to £362.90) for the efBDP-FOR group, a difference
of £93.63/patient/year (95% CI £73.65 to £114.27), or
£7.89/patient/month.
The single greatest contributor to the total healthcare cost was
Figure 2.  Actual ICS dosage prescribed at the Index
Prescription Date in patients remaining on FP-SAL and
those switched to efBDP-FOR (values for the efBDP-FOR
group are actual BDP dosages, not FP-equivalents)
BDP=beclometasone dipropionate, efBDP-FOR=extra-fine particle
beclometasone and formoterol as fixed-dose combination inhaler,
FP=fluticasone propionate, FP-SAL=fluticasone and salmeterol as fixed-dose
combination inhaler, ICS=inhaled corticosteroid.
Severe exacerbations FP-SAL efBDP-FOR
(n=1,146) (n=382)
0, n (%) 918 (80.1%) 309 (80.9%)
1, n (%) 155 (13.5%) 49 (12.8%)
2+, n (%) 73 (6.4%) 24 (6.3%)
p=0.78
Adjusted rate ratio* 1.00 1.01
95% CI – 0.74 to 1.37
*Adjusted for baseline confounders: numbers of SABA prescriptions and 
asthma consultations.
ATS/ERS=American Thoracic Society and European Respiratory Society, 
CI=confidence intervals, efBDP-FOR=extra-fine particle beclometasone and 
formoterol as fixed-dose combination inhaler, FP-SAL=fluticasone and salmeterol 
as fixed-dose combination inhaler, SABA=short-acting β2-receptor agonist
Table 4. Comparison of severe exacerbation rates
(ATS/ERS definition) between matched treatment
groups during the outcome year
Outcome FP-SAL efBDP-FOR
(n=1,146) (n=382)
Overall asthma control (risk and impairment)
Adjusted odds ratio* 1.00 1.56
(95% CI) (1.14 to 2.14)
Average daily SABA usage
Adjusted odds ratio* 1.00 0.74
(95% CI) (0.60 to 0.91)
Adherence to ICS therapy
Odds ratio 1.00 1.40
(95% CI) (1.13 to 1.73)
*Adjusted for baseline confounders (see Table 5b in online Supplemental Materials)
CI=confidence intervals, efBDP-FOR=extra-fine particle beclometasone and 
formoterol as fixed-dose combination inhaler, FP-SAL=fluticasone and salmeterol 
as fixed-dose combination inhaler, ICS=inhaled corticosteroid, SABA=short-acting 
β2-receptor agonist.
Table 5a. Comparison of secondary outcomes between
matched treatment groups during the outcome year (for
the full version of this table, see Table 5b in online
Supplemental Materials)
Figure 3.  Adherence to ICS therapy in matched
treatment groups during their baseline and outcome
years (patients in the ‘efBDP-FOR baseline’ group were
on FP-SAL during their baseline year but were switched
to efBDP-FOR at the index prescription date.)
Adherence was categorised as <50%, 50–69%, 70–99%, and 100+%
compliance with the prescribed ICS dosage. *Adherence to ICS therapy was
significantly greater in the efBDP-FOR patients than in the FP-SAL patients
during the outcome year (p=0.001). efBDP-FOR=extra-fine particle
beclometasone and formoterol as fixed-dose combination inhaler, FP-
SAL=fluticasone and salmeterol as fixed-dose combination inhaler,
ICS=inhaled corticosteroid.
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the cost of FDC inhaler therapy, so these differences were driven by
the significantly lower cost of FDC inhaler therapy in the efBDP-FOR
group (p<0.001). All other costs (drugs, consultations,
hospitalisations) were comparable between treatment groups. The
mean cost of FDC inhaler therapy for the outcome year was
£368.20/patient for the FP-SAL group and £280.12/patient for the
efBDP-FOR group, a difference of £88.08/patient/year, or
£7.34/patient/month.
Based on point estimates of differences in cost and effectiveness
using 1,000 replicated samples, efBDP-FOR was both less costly and
more effective than FP-SAL in this setting. Using exacerbation
prevention (ATS/ERS definition) as the measure of treatment
effectiveness, there was a 75% probability that efBDP-FOR is less
costly and more effective than FP-SAL (Figure 4). Using risk domain
asthma control as the measure of effectiveness, there was an 87%
probability that efBDP-FOR is less costly and more effective in this
setting. 
Discussion
Main findings 
In this heterogeneous population of patients requiring ICS-LABA
therapy for asthma control, efBDP-FOR was at least as effective as FP-
SAL in preventing severe exacerbations. In addition, switching from
FP-SAL to efBDP-FOR at an equivalent or lower daily ICS dosage
resulted in improved odds of achieving overall asthma control, lower
daily SABA usage, and better adherence to ICS therapy, all at a lower
daily ICS dosage. Furthermore, switching from FP-SAL to efBDP-FOR
was cost-effective, efBDP-FOR being more effective and less costly
than FP-SAL in this patient population.     
Strengths and limitations of this study           
There are three main strengths of our study: (1) its large and diverse
patient population, with few clinically relevant exclusion criteria; (2)
its relatively long duration; and (3) its non-interventional nature. By
including patients with significant co-morbidities, smokers, and
patients with poor adherence to their ICS prescription, most of the
challenges typically faced in primary asthma care were represented
in our study population. In addition, our study examined 12 months
of patient data both before and after the index patient
review/switch, so the effects of seasonal or other transient
confounders – including a change in therapy – were minimised.
Furthermore, the retrospective nature of data acquisition meant that
our study protocol did not affect patient behaviour in any way,
particularly with respect to inhaler use and physician contact.
In contrast, the RCTs which compared efBDP-FOR with FP-SAL15
and BUD-FOR26 followed only 114 and 109/110 carefully selected
patients, respectively, and for a treatment period of only 12 weeks.
Furthermore, those study protocols required frequent clinic visits over
the course of the investigation period,15,26 which likely influenced
treatment adherence and thus outcomes.43,44 Our study showed that
efBDP-FOR is comparable to FP-SAL – and in some measures superior
– in real-life asthma patients.
The main limitations of our study are those inherent to
retrospective studies, and to observational studies of any kind.43,44
There are trade-offs in the scope and thus the findings of any study.
Specifically, our study design precluded a thorough evaluation of
adverse effects with either ICS-LABA combination in this patient
population. In order to achieve our objectives, it was necessary to
include only those patients with complete data for both baseline and
outcome years. Our study design thus precluded an evaluation of
asthma-related deaths and other rare significant adverse effects with
either FDC inhaler.
Another limitation of our study was the need to rely on
anonymised medical records for the diagnosis of asthma and the
exclusion of other chronic respiratory disorders such as chronic
obstructive pulmonary disease (COPD). Using diagnostic spirometry, it
has been estimated that about 25% of asthma patients over the age
of 40 may have COPD.45 Given the age distribution and smoking
status of the patients in our study, we estimate that a maximum of
10% of the patients may have had COPD instead of – or in addition
Figure 4.  Cost-effectiveness of switching from FP-SAL to
efBDP-FOR, with treatment effectiveness based on
exacerbation prevention (ATS/ERS definition) during the
outcome year. Costs are total asthma-related healthcare
costs (£/patient/year), adjusted for baseline differences
FP-SAL efBDP-FOR
(n=1,146) (n=382)
Average daily ICS dose, n (%)
1–200 μg 203 (17.7%) 92 (24.1%)
201–400 μg 350 (30.6%) 197 (51.5%)
401–600 μg 352 (30.7%) 74 (19.4%)
601+ μg 241 (21.0%) 19 (5.0%)
Mean (SD), μg/day 455.0 (304.8) 324.5 (159.3)
Median (IQR) μg/day 411.0 (246.6, 575.4) 295.9 (230.2, 394.5)
p Value* <0.001
*Conditional logistic regression.
efBDP-FOR=extra-fine particle beclometasone and formoterol as fixed-dose 
combination inhaler, FP=fluticasone propionate, FP-SAL=fluticasone and 
salmeterol as fixed-dose combination inhaler, ICS=inhaled corticosteroid, 
IQR=interquartile range, SD=standard deviation.
Table 6. Comparison of average daily ICS dose (FP-
equivalents) between matched treatment groups during
the outcome year
ATS/ERS=American Thoracic Society and European Respiratory Society, 
efBDP-FOR=extra-fine particle beclometasone and formoterol as fixed-dose
combination inhaler, FP-SAL=fluticasone and salmeterol as fixed-dose
combination inhaler.
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to – asthma. As age and smoking status were matching variables,
any such patients would have been fairly equally distributed among
the two treatment groups.
Interpretation of findings in relation to previously
published work           
The clinical effectiveness of efBDP-FOR in asthma patients requiring
combination ICS-LABA therapy is well established.12-16,21-27,46,47 However,
to our knowledge, no studies have evaluated both the clinical and cost
effectiveness of switching from another ICS-LABA combination to
efBDP-FOR in the typical asthma patient – a scenario that is likely to be
increasingly common in primary care, given the substantially lower cost
and comparable effectiveness of the efBDP-FOR inhaler and, in the UK,
certain NHS recommendations to physicians.2
The effectiveness of stepping down from high-dose FP-SAL to
moderate-dose FP-SAL (step-down) or efBDP-FOR (step-down plus
switch) was recently shown in a prospective RCT. The study
concluded that efBDP-FOR (400μg/day efBDP) was equivalent to
moderate-dose FP-SAL (500μg/day FP) in morning pre-dose peak
expiratory flow, and asthma control was maintained in 96% of the
patients following treatment step-down (from 1,000μg/day FP).14 In
another recent RCT, asthma patients previously controlled with FP-
SAL (500μg/day FP) were effectively stepped across or switched to
efBDP-FOR (400μg/day efBDP); lung function and asthma control
were maintained, no safety issues were reported, and efBDP-FOR
was noted to have a relatively rapid (5 min) onset of action.25
However, those studies involved carefully selected patient
populations, as is typical of a RCT, and did not include cost analyses.
An Italian study48 conducted a post hoc cost-effectiveness and
cost-utility analysis of the data from the RCT on which the non-
inferiority of efBDP-FOR to FP-SAL was based.15 From the perspective
of the Italian NHS, efBDP-FOR was more cost effective than FP-SAL
and offered a slight advantage over FP-SAL in weeks spent
successfully controlled and in quality-adjusted life years.48 However,
that study involved only 114 carefully selected patients in each
treatment group and followed the patients for only 12 weeks of
treatment.15 None of these RCTs examined a broad population of
asthma patients.
The PRISMA (PRospectIve Study on asthMA control) study group
followed 1,017 real-life asthma patients for 12 months, including
smokers, ex-smokers, and patients with co-morbidities.24,27 Of the
739 patients evaluable after 12 months, 569 patients were treated
using an ICS-LABA combination. The patients on efBDP-FOR had
significantly better asthma control and quality of life compared with
patients on FP-SAL or BUD-FOR.24 In another study of real-life asthma
patients, treatment with efBDP-FOR led to significant improvements
in pulmonary function and asthma control, regardless of the patient's
smoking status, and the medication was well tolerated.47 However,
while these studies indicate that efBDP-FOR is both safe and effective
for asthma control in typical asthma patients, a study of real-life
asthma patients switching from FP-SAL to efBDP-FOR was necessary
in order to confirm that switching is both clinically and cost effective
in this broad patient population.
Implications for future research, policy and practice    
One direction for future research is the outcome, in clinical and cost
effectiveness, of stepping down the ICS dosage in typical asthma
patients switching to efBDP-FOR from another ICS-LABA
combination. The British Thoracic Society and Scottish Intercollegiate
Guidelines Network recommend stepping down ICS therapy once
asthma is controlled, advising a treatment review every three months
and a decrease in dosage by approximately 25–50% each time if
appropriate.49 Only 86 patients in our study were switched to efBDP-
FOR at an ICS dosage that was substantially lower than their last FP-
SAL prescription, so meaningful statistical analysis was not possible. 
Another avenue worth exploring is the use of efBDP-FOR as
single inhaler MART. A recent RCT found that efBDP-FOR used both
for daily maintenance and as-needed reliever therapy was well
tolerated and superior to a combination of daily maintenance with
efBDP-FOR and as-needed SABA (salbutamol). The MART approach
with efBDP-FOR significantly increased the time to first severe
exacerbation (ATS/ERS definition) by 75 days, reduced the risk of
exacerbation by 36%, and resulted in fewer courses of oral steroids
and asthma-related hospitalisations compared with the efBDP-FOR +
SABA combination.22 It would be interesting to evaluate the cost
effectiveness of this approach, as it is possible that even further
asthma-related cost savings could be realised without a significant
reduction in clinical effectiveness or an increase in risk.
Conclusions   
Switching asthma patients from FP-SAL to efBDP-FOR at an
equivalent or lower ICS dosage is both less costly and more effective.
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Materials and methods  
The FP-SAL inhalers under investigation were the Seretide®
Accuhaler and the Seretide® Evohaler (Allen & Hanburys Ltd,
Uxbridge, Middlesex, UK). Each single dose of the Accuhaler
contains 100, 250, or 500μg of fluticasone propionate and 50μg of
salmeterol xinafoate. Each single actuation of the Evohaler contains
50, 125, or 250μg of fluticasone propionate and 25μg of salmeterol
xinafoate. The efBDP-FOR inhaler was Fostair® 100/6 (Chiesi Ltd,
Highfield, Cheadle, UK). Each metered dose contains 100μg of
extra-fine particle beclometasone dipropionate and 6μg of
formoterol fumarate dihydrate. The Fostair inhaler uses Modulite
technology, so it generates a slower plume of aerosolised
medication than earlier formulations, which may help with
pulmonary deposition.1
Study design 
The baseline year of data collection was used for patient matching,
to identify and characterise any confounders, and to allow for
seasonal changes in respiratory disease and its related conditions. It
also established that the patients were relatively well controlled on
FP-SAL at their current dosage, as at the index review the physician
saw no need to increase the ICS dosage. This aspect of the study
design was important in comparing the two FDC inhalers on equal
footing while examining the results of the switch.
Figure S1 summarises the patient selection process prior to case
matching. The databases identified 1,113,776 patients who were
being treated with ICS therapy. Patients were considered for
inclusion if they received a prescription for either FP-SAL or efBDP-
FOR as single FDC inhaler therapy after 1 January 2008 and received
no other ICS or LABA prescriptions on the same date. On this basis,
930,645 patients were excluded.
Patients further considered for inclusion had a recorded
diagnostic code for asthma; no recorded diagnosis for chronic
obstructive pulmonary disease or other chronic respiratory disease;
at least two prescriptions for FP-SAL as FDC inhaler therapy during
their baseline year; either ongoing prescriptions for FP-SAL with no
change in ICS dosage or switch to efBDP-FOR at an ICS dosage
equivalent to, or lower than, their last FP-SAL prescription (>2
efBDP-FOR prescriptions) in their outcome year; and attended a
practice in which five or more patients were switched from FP-SAL
to efBDP-FOR within a three-month period. On this basis, 105,631
patients were excluded.
Even patients who met all other inclusion criteria but whose
prescribed ICS dosage was increased at the index prescription date
(IPD) were excluded. This step was taken in an effort to determine
fairly whether efBDP-FOR was at least equivalent to FP-SAL when
patients are switched as recommended by the NHS.2,3 The study
group was limited to the patients of primary care practices switching
multiple patients from FP-SAL to efBDP-FOR over a short period of
time, as this “wholesale” change in prescribing suggests that the
switch was made for reasons other than clinical efficacy, such as
lower ICS dosage for safety/tolerance and/or cost.
Of the remaining 77,500 patients under consideration, the final
selection process included those who were between 18 and 80
years of age; had complete data for both the baseline and outcome
years; whose smoking status was known; and who required no oral
corticosteroids for maintenance during their baseline year. A total of
50,261 patients met these last inclusion criteria, of whom 390 were
switched to efBDP-FOR and 49,871 remained on FP-SAL for the
outcome year. Figure S2 illustrates the subsequent case matching
process.
Statistical analysis  
Exploratory data analysis was conducted for all variables of interest
for both the baseline and outcome years. As a conservative
approach, differences between treatment groups were considered
possibly important if p<0.10. Variables meeting this criterion were
examined for co-linearity and clinical importance to select those
used as potential confounders (Box 2) in the regression modelling of
outcomes.
Data plots
During exploratory data analysis, frequency distribution plots were
generated to illustrate the distribution of variables measured on the
interval or ratio scale and to determine whether categorisation was
necessary (eg, if heavily skewed). Box plots were generated to
illustrate the location and spread of the variable and identify
potential outliers. Plots by treatment group were used to highlight
baseline and outcome differences between treatment groups. For
categorical variables, mosaic plots were generated to illustrate
distributions and highlight baseline and outcome differences
between treatment groups.
Correlations 
Spearman correlation coefficients were calculated among all
baseline variables to determine strengths of linear relationships
between variables. Relationships with rank correlation coefficients
>0.30 were considered, in conjunction with clinical interpretation, to
identify pairings of variables that may present co-linearity issues at
the modelling stage. Scatter plots and error bar plots were used to
further investigate non-linear relationships.
Predictive variables
Multivariate analyses were conducted using the full dataset to
identify baseline variables that were predictive (p<0.05) of
outcomes. These variables were then considered as potential
confounders when modelling the outcome variables.
Clinical outcomes, primary
Exacerbation rates were compared across treatment arms using a
conditional Poisson regression model. The model used empirical
standard errors (for more conservative CI estimations), and
adjustments were made for potential baseline confounders.
Variables that were significantly different – or showed a trend
towards significance – between treatment groups at baseline were
included as potential confounding factors. Variables that were
found to be predictive (p<0.05) of the outcome through multivariate
analysis were also considered as potential confounders.
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Clinical outcomes, secondary
The adjusted odds of achieving risk domain asthma control (RDAC),
overall asthma control (OAC), and treatment success (TS) were
compared between matched treatment groups using conditional
binary logistic regression models. For RDAC and OAC, asthma
control status was used as the dependent variable, with treatment
and potential confounding factors as explanatory variables. For TS,
success status was used as the dependent variable, with treatment
and potential confounding factors as explanatory variables.
The total number of exacerbations (clinical definition),
hospitalisations (where event numbers were sufficient), and
incidents of oral thrush were compared between treatment groups
using a conditional Poisson regression model to obtain an estimate
of relative exacerbation, hospitalisation, and incident rates. The
model used empirical standard errors (for more conservative CI
estimations) and adjustments were made for potential baseline
confounders.
The adjusted odds of being in a higher ICS adherence or SABA
category were compared between matched treatment groups using
conditional ordinal logistic regression models. The adherence or
SABA category was used as the dependent variable, with treatment
and potential confounding factors as explanatory variables.
Variables that were significantly different or showed a trend
toward significance (p<0.10) between treatment groups at baseline
were included as potential confounding factors. In addition,
variables that were found to be predictive (p<0.05) of the outcome
through multivariate analysis were also considered as potential
confounders.
Results 
Tables 3b and 3c show other clinically important baseline variables
for the matched treatment groups. Table 5b provides full details of
the secondary clinical outcome measures between matched
treatment groups during the outcome year. 
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Figure S1.  CONSORT diagram of patient selection for the Real-world Effectiveness in Asthma therapy of Combination
inHalers (REACH) study. *An event comprised a repeat prescription for FP-SAL. Each repeat prescription was counted
as a separate event, so patients may have had multiple events. This step was taken to ensure that enough eligible
patients prescribed ongoing FP-SAL therapy were available so that each qualified efBDP-FOR patient could be closely
matched with three unique FP-SAL patients (see Figure S2)
COPD=chronic obstructive pulmonary disease, efBDP-FOR=extra-fine particle beclometasone and formoterol as fixed-dose combination
inhaler, FP-SAL=fluticasone and salmeterol as fixed-dose combination inhaler, ICS=inhaled corticosteroid.
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Figure S2.  CONSORT diagram of patient matching for the Real-world Effectiveness in Asthma therapy of Combination
inHalers (REACH) study. *An event comprised a repeat prescription for FP-SAL (see explanation in Figure S1)
efBDP-FOR=extra-fine particle beclometasone and formoterol as fixed-dose combination inhaler, FP-SAL=fluticasone and salmeterol as 
fixed-dose combination inhaler, ICS=inhaled corticosteroid, SABA=short-acting β2-receptor agonist.
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Potential confounders examined at (or closest to) the index prescription 
date (IPD):
• Age
• Gender
• Height
• Weight
• Body mass index (BMI) (where BMI can be evaluated)
• Lung function, as indicated by % predicted peak expiratory flow 
(calculated using age-specific equations for patients 18 years of age1
and those over 18 years2)
• Smoking status
Potential confounders examined regardless of when they occurred relative 
to the IPD:
• Date of first asthma diagnosis
• Other respiratory or confounding diagnoses, including:
o  Rhinitis
o  Gastroesophageal reflux disease (GERD)
o  Cardiac disease
o  Eczema
Potential confounders examined in the year before the IPD:
• Presence/absence of co-morbid rhinitis (diagnosis ever and/or 
prescriptions for rhinitis therapy in the prior/outcome year)
• Presence/absence of co-morbid eczema (diagnosis ever and/or 
prescriptions for eczema therapy in the prior/outcome year)
• Presence of GERD (diagnosis ever and/or prescriptions for GERD therapy 
in the prior/outcome year)
• Other important unrelated co-morbidities using a modified Charlson 
Comorbidity Index3
• Number of exacerbations in year prior to the IPD
• Number of acute courses of oral steroids in the year prior to the IPD
• Number of hospitalisations for asthma/lower respiratory reasons or 
possibly asthma/lower respiratory-related (a non-specific hospitalisation 
code and an asthma/lower respiratory code within one week)
• Number of hospital outpatient attendances in the prior year where 
asthma and/or lower respiratory illness was the reason for referral
• Number of prescriptions for any antibiotic in the prior year where 
the reason for the prescription was lower respiratory tract infection
• Number of prescriptions for any respiratory therapy (split by number of 
prescriptions for each) in the prior year
• Other medications, number of prescriptions for the following in the year 
prior to the IPD:
o  Paracetamol
o  Non-steroidal anti-inflammatory drugs (NSAIDs)
o  Beta-blockers
o  Theophylline
• Number of primary care consultations in the year prior
• Number of asthma consultations in the year prior
• Number of asthma consultations in the prior year that did not result in
asthma exacerbation treatment
• Average short-acting β2 agonist (SABA) daily dose (total combined 
dose of refilled prescriptions, averaged over 365 days)
• Number of SABA prescriptions received in the prior year
• Average inhaled corticosteroid (ICS) daily dose during the prior year 
(total combined dose of refilled prescriptions, averaged over 365 days)
• Adherence to ICS therapy (see Table 2 in main text)
• Spacer use/prescription
• Oral thrush
1. Rosenthal M, Cramer D, Bain SH, Denison D, Bush A, Warner JO. Lung function
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plethysmography. Thorax 1993;48(8):803-08.
2. Roberts CM, MacRae KD, Winning AJ, Adams L, Seed WA. Reference values and
prediction equations for normal lung function in a non-smoking white urban
population. Thorax 1991;46(9):643–50.
3. Aylin P, Bottle A, Jen MH, Middleton S. HSMR mortality indicators (article on the
internet). London: Doctor Foster Research, 26 Nov 2010. Available online from
http://www.drfosterhealth.co.uk/docs/HSMR?methodology?Nov?2010.pdf
(accessed 15 March 2013).
Box 2. Potential confounders examined in the initial
analysis
Variable FP-SAL efBDP-FOR* p Value†
(n=1,146) (n=382)
Severe exacerbation rate (ATS/ERS definition)
0 928 (81.0%) 312 (81.7%) 1.000
1 149 (13.0%) 46 (12.0%)
2+ 69 (6.0%) 24 (6.3%)
Mean (SD) 0.29 (0.76) 0.34 (1.13) 0.112
Median (IQR) 0 (0, 0) 0 (0, 0)
Risk domain asthma control
Controlled 761 (66.4%) 260 (68.1%) 0.415
Overall asthma control
Controlled 389 (33.9%) 135 (35.3%) 0.297
Severe exacerbation rate (clinical definition)
0 782 (68.2%) 263 (68.8%) 0.816
1 237 (20.7%) 79 (20.7%)
2+ 127 (11.1%) 40 (10.5%)
Mean (SD) 0.51 (0.94) 0.55 (1.26) 0.286
Median (IQR) 0 (0, 1) 0 (0, 1)
Inpatient asthma-related hospitalisations
0 1,138 (99.3%) 381 (99.7%) 0.355
1+ 8 (0.7%) 1 (0.3%)
Adherence to ICS therapy
<50% 231 (20.2%) 70 (18.3%) 0.282
50–69% 237 (20.7%) 76 (19.9%)
70–99% 415 (36.2%) 142 (37.2%)
100+% 263 (22.9%) 94 (24.6%)
Mean (SD) 82.0 (40.5) 82.6 (34.1) 0.783
Median (IQR) 80 (54, 99) 81 (57, 99)
Incidence of oral thrush
Diagnosis 5 (0.4%) 3 (0.8%) 0.421
Diagnosis or antifungal 20 (1.7%) 10 (2.6%) 0.295
therapy
All values are n (%) unless otherwise stated.
*These patients were on FP-SAL during their baseline year but were switched 
to efBDP-FOR at the index prescription date.
†Conditional logistic regression.
ATS/ERS=American Thoracic Society and European Respiratory Society, 
efBDP-FOR=extra-fine particle beclometasone and formoterol as 
fixed-dose combination inhaler, FP-SAL=fluticasone and salmeterol as 
fixed-dose combination inhaler, ICS=inhaled corticosteroid, IQR=interquartile 
range, SD=standard deviation.
Table 3b. Clinically important baseline variables in
matched treatment groups: primary and secondary
outcome measures
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Variable FP-SAL efBDP-FOR* p 
(n=1,146) (n=382) Value†
Co-morbidities
Rhinitis‡ 495 (43.2%) 143 (37.4%) 0.047
Cardiac disease 178 (15.5%) 34 (8.9%) 0.001
Asthma consultations
0 255 (22.3%) 53 (13.9%) <0.001
1 500 (43.6%) 165 (43.2%)
2+ 391 (34.1%) 164 (42.9%)
Mean (SD) 1.43 (1.38) 1.70 (1.44) <0.001
Median (IQR) 1 (1, 2) 1 (1, 2)
Respiratory prescriptions (all scripts)
Mean (SD) 11.0 (7.4) 13.2 (8.6) <0.001
Median (IQR) 9 (6, 14) 11 (7, 17)
ICS scripts
Mean (SD) 6.2 (3.4) 7.5 (3.3) <0.001
Median (IQR) 5 (4, 8) 7 (5, 10)
SABA scripts
Mean (SD) 3.8 (3.7) 4.5 (4.6) <0.001
Median (IQR) 3 (1, 5) 3 (1, 6)
Average daily ICS dosage (μg/day)
1–200 295 (25.7%) 70 (18.3%) 0.015
201–400 409 (35.7%) 150 (39.3%)
401–600 285 (24.9%) 111 (29.1%)
601+ 157 (13.7%) 51 (13.3%)
Mean (SD) 374.9 (255.2) 388.0 (241.0) 0.253
Median (IQR) 329 (197, 493) 329 (206, 493)
LRTI consultations resulting in antibiotic prescription
0 916 (79.9%) 312 (81.7%) 0.520
1 167 (14.6%) 50 (13.1%)
2+ 63 (5.5%) 20 (5.2%)
Mean (SD) 0.28 (0.65) 0.27 (0.67) 0.729
Median (IQR) 0 (0, 0) 0 (0, 0)
Controller-reliever ratio
<0.5 193 (16.8%) 48 (12.6%) 0.017
>0.5 953 (83.2%) 334 (87.4%)
All values are n (%) unless otherwise stated.
*These patients were on FP-SAL during their baseline year but were 
switched to efBDP-FOR at the index prescription date.
†Conditional logistic regression.
‡Rhinitis diagnosis or nasal spray use.
efBDP-FOR=extra-fine particle beclometasone and formoterol as fixed-dose 
combination inhaler, FDC=fixed-dose combination inhaler, 
FP-SAL=fluticasone and salmeterol as fixed-dose combination inhaler, 
ICS=inhaled corticosteroid, IQR=interquartile range, LRTI=lower respiratory 
tract infection, SABA=short-acting β2-receptor agonist, SD=standard 
deviation.
Table 3c. Clinically important baseline variables in
matched treatment groups: other clinically
relevant variables Outcome FP-SAL efBDP-FOR
(n=1,146) (n=382)
Risk domain asthma control
Controlled 786 (68.6%) 277 (72.5%)
Adjusted odds ratio* (95% CI) 1.00 1.15 (0.88 to 1.52)
Overall asthma control (risk and impairment)
Controlled 358 (31.2%) 149 (39.0%)
Adjusted odds ratio† (95% CI) 1.00 1.56 (1.14 to 2.14)
Also adjusted for BMI‡ (95% CI) 1.00 1.53 (1.10 to 2.11)
Severe exacerbation rate (clinical definition)
0 812 (70.9%) 280 (73.3%)
1 211 (18.4%) 62 (16.2%)
2+ 123 (10.7%) 40 (10.5%)
Adjusted rate ratio§ (95% CI) 1.00 1.01 (0.80 to 1.29)
Treatment success
Successful 727 (63.4%) 263 (68.8%)
Adjusted odds ratio¶  (95% CI) 1.00 1.24 (0.95 to 1.62)
Average daily SABA usage (μg)
0 173 (15.1%) 55 (14.4%)
1–100 325 (28.4%) 128 (33.5%)
101–200 320 (27.9%) 90 (23.6%)
201–400 252 (22.0%) 91 (23.8%)
401+ 76 (6.6%) 18 (4.7%)
Adjusted odds ratio** (95% CI) 1.00 0.74 (0.60 to 0.91)
Adherence to ICS therapy (%)
<50 314 (27.4%) 79 (20.7%)
50–69 174 (15.2%) 53 (13.9%)
70–99 377 (32.9%) 131 (34.3%)
100+ 281 (24.5%) 119 (31.1%)
Odds ratio (95% CI) 1.00 1.40 (1.13 to 1.73)
Inpatient asthma-related hospitalisations
1+ 28 (2.4%) 7 (1.8%)
Adjusted rate ratio†† (95% CI) 1.00 0.67 (0.30 to 1.49)
Incidence of oral thrush
1+ 29 (2.5%) 16 (4.2%)
Adjusted rate ratio‡‡ (95% CI) 1.00 1.59 (0.77 to 3.27)
Values are n (%) unless otherwise stated.
*Adjusted for baseline confounders: (consultations for LRTIs resulting in a course 
of antibiotics (categorised), allergy prescriptions (categorised), and asthma-related 
Outpatient Department attendance (yes/no).
†Adjusted for: rhinitis diagnosis and/or therapy (yes/no), cardiac disease diagnosis (yes/no), 
asthma consults with no oral steroid script (categorised), SABA scripts (categorised), single 
inhaler ICS use (yes/no), and LRTI consults resulting in antibiotics (categorised).
‡BMI: body mass index (categorised).
§Adjusted for: acute oral steroids (categorised), LRTI consults resulting in antibiotics 
(categorised), allergy scripts (categorised), and asthma consults (categorised).
¶Adjusted for: asthma consults with no oral steroid script (categorised), SABA scripts 
(categorised), and allergy scripts (categorised).
**Adjusted for: asthma consults (categorised), scripts for separate ICS inhalers (yes/no), 
and SABA scripts (categorised).
††Adjusted for: primary care consults (categorised).
‡‡Adjusted for: asthma consults (categorised), non-asthma-related consults (categorised), 
and baseline incidence of oral thrush (yes/no).
CI=confidence intervals, efBDP-FOR=extra-fine particle beclometasone and formoterol as 
fixed-dose combination inhaler, FP-SAL=fluticasone and salmeterol as fixed-dose 
combination inhaler, ICS=inhaled corticosteroid, LRTI=lower respiratory tract infection, 
SABA=short-acting β2-receptor agonist.
Table 5b. Comparison of secondary outcomes between
matched treatment groups during the outcome year
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